B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2012 Apr 9;172(7):540-7.

doi: 10.1001/archinternmed.2011.1450. Epub 2012 Feb 13.

Affiliations

• PMID: 22331983
• DOI: 10.1001/archinternmed.2011.1450

Randomized Controlled Trial

B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial

Valentina A Andreeva et al. Arch Intern Med. 2012.

Abstract

Background: To advance knowledge about the cancer-chemopreventive potential of individual nutrients, we investigated the effects of B vitamin and/or ω-3 fatty acid supplements on cancer outcomes among survivors of cardiovascular disease.

Methods: This was an ancillary study of the Supplementation With Folate, Vitamins B(6) and B(12) and/or Omega-3 Fatty Acids (SU.FOL.OM3) secondary prevention trial (2003-2009). In all, 2501 individuals aged 45 to 80 years were randomized in a 2 × 2 factorial design to one of the following 4 daily supplementation groups: (1) 5-methyltetrahydrofolate (0.56 mg), pyridoxine hydrochloride (vitamin B(6); 3 mg) and cyanocobalamin (vitamin B(12); 0.02 mg); (2) eicosapentaenoic and docosahexaenoic acid (600 mg) in a 2:1 ratio; (3) B vitamins and ω-3 fatty acids; or (4) placebo. Overall and sex-specific hazard ratios (HRs) and 95% CIs regarding the cancer outcomes were estimated with Cox proportional hazards models.

Results: After 5 years of supplementation, incident cancer was validated in 7.0% of the sample (145 events in men and 29 in women), and death from cancer occurred in 2.3% of the sample. There was no association between cancer outcomes and supplementation with B vitamins (HR, 1.15 [95% CI, 0.85-1.55]) and/or ω-3 fatty acids (HR, 1.17 [95% CI, 0.87-1.58]). There was a statistically significant interaction of treatment by sex, with no effect of treatment on cancer risk among men and increased cancer risk among women for ω-3 fatty acid supplementation (HR, 3.02 [95% CI, 1.33-6.89]).

Conclusion: We found no beneficial effects of supplementation with relatively low doses of B vitamins and/or ω-3 fatty acids on cancer outcomes in individuals with prior cardiovascular disease. Trial Registration isrctn.org Identifier: ISRCTN41926726.

PubMed Disclaimer

Similar articles

• Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial.
  Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Andreeva VA, et al. Am J Clin Nutr. 2011 Jul;94(1):278-86. doi: 10.3945/ajcn.110.006320. Epub 2011 May 18. Am J Clin Nutr. 2011. PMID: 21593490 Clinical Trial.
• [Does diet affect our mood? The significance of folic acid and homocysteine].
  Karakuła H, Opolska A, Kowal A, Domański M, Płotka A, Perzyński J. Karakuła H, et al. Pol Merkur Lekarski. 2009 Feb;26(152):136-41. Pol Merkur Lekarski. 2009. PMID: 19388520 Review. Polish.
• [Nutritional medicine 2007].
  Hauner H. Hauner H. Dtsch Med Wochenschr. 2007 Jun 22;132(25-26):1411-3. doi: 10.1055/s-2007-982046. Dtsch Med Wochenschr. 2007. PMID: 17570092 Review. German. No abstract available.

Cited by

• Healthy Aging-Nutrition Matters: Start Early and Screen Often.
  Roberts SB, Silver RE, Das SK, Fielding RA, Gilhooly CH, Jacques PF, Kelly JM, Mason JB, McKeown NM, Reardon MA, Rowan S, Saltzman E, Shukitt-Hale B, Smith CE, Taylor AA, Wu D, Zhang FF, Panetta K, Booth S. Roberts SB, et al. Adv Nutr. 2021 Jul 30;12(4):1438-1448. doi: 10.1093/advances/nmab032. Adv Nutr. 2021. PMID: 33838032 Free PMC article. Review.
• Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
  Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group. Manson JE, et al. N Engl J Med. 2019 Jan 3;380(1):23-32. doi: 10.1056/NEJMoa1811403. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415637 Free PMC article. Clinical Trial.
• Homocysteine-lowering interventions for preventing cardiovascular events.
  Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review.
• Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
  Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L. Abdelhamid AS, et al. Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD012345. doi: 10.1002/14651858.CD012345.pub2. Cochrane Database Syst Rev. 2018. PMID: 30019767 Free PMC article. Updated. Review.
• Update on the Vitamin D and OmegA-3 trial (VITAL).
  Pradhan AD, Manson JE. Pradhan AD, et al. J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):252-6. doi: 10.1016/j.jsbmb.2015.04.006. Epub 2015 Apr 9. J Steroid Biochem Mol Biol. 2016. PMID: 25864623 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information